Cannabinoids in rheumatology: potential pain benefits weighed against drug interactions and side effects
A narrative review found that while cannabinoids show some benefits for pain in rheumatoid arthritis, osteoarthritis, and fibromyalgia, drug interactions with common rheumatology medications and adverse effects tilt the balance toward caution.
Quick Facts
What This Study Found
Cannabinoids act through CB1 and CB2 receptors with potential analgesic effects. Some benefits were found for rheumatoid arthritis, osteoarthritis, and fibromyalgia. However, cannabinoids have potential interactions with common rheumatology drugs that many users are unaware of, and the review concluded on balance that cannabinoids are more "foe" than "friend" for rheumatology.
Key Numbers
613 articles screened. Two major cannabinoid receptor types (CB1, CB2) reviewed. Despite NHS guidelines against cannabinoid use for chronic pain, patients increasingly use them without prescriptions.
How They Did This
Narrative review searching PubMed for "Cannabinoids," "Rheumatology," and "Chronic pain." Screened 613 articles for mechanism of action, adverse effects, and drug interactions. Included musculoskeletal librarian consultation.
Why This Research Matters
Rheumatology patients increasingly use cannabinoids for pain without prescription, often unaware of potential interactions with their prescribed medications. This review directly addresses a knowledge gap in clinical practice.
The Bigger Picture
The disconnect between patient behavior (using cannabinoids for pain relief) and clinical guidelines (recommending against it) creates a practical challenge. The drug interaction risks add an additional layer of concern for patients on multiple medications.
What This Study Doesn't Tell Us
Narrative review methodology is less rigorous than systematic review. Concluded "foe" based on risk-benefit balance, which involves subjective judgment. Drug interaction evidence is primarily theoretical for many rheumatology medications.
Questions This Raises
- ?Which specific rheumatology drugs have the most dangerous interactions with cannabinoids?
- ?Could monitored cannabinoid use be safer than unmonitored self-medication?
Trust & Context
- Key Stat:
- 613 articles screened; drug interactions identified with common RA medications
- Evidence Grade:
- Narrative review covering mechanism, efficacy, and drug interactions, but without systematic methodology.
- Study Age:
- Published in 2022.
- Original Title:
- Cannabinoids in rheumatology: Friend, foe or a bystander?
- Published In:
- Musculoskeletal care, 20(2), 416-428 (2022)
- Authors:
- Jain, Nibha, Moorthy, Arumugam
- Database ID:
- RTHC-03928
Evidence Hierarchy
Summarizes existing research without a strict systematic method.
What do these levels mean? →Frequently Asked Questions
Can cannabis help with arthritis pain?
The review found some evidence of benefits for rheumatoid arthritis, osteoarthritis, and fibromyalgia, but drug interactions with common rheumatology medications and side effects led the authors to conclude cannabinoids are more risky than helpful overall.
Does cannabis interact with arthritis medications?
Yes. The review identified potential interactions between cannabinoids and common rheumatology drugs that many patients using cannabis are unaware of, adding risk beyond the side effects of cannabis itself.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-painkillers-opioid-interactions
- thc-and-muscle-relaxers-combining
- thc-and-ibuprofen-safe-combine-research
Cite This Study
https://rethinkthc.com/research/RTHC-03928APA
Jain, Nibha; Moorthy, Arumugam. (2022). Cannabinoids in rheumatology: Friend, foe or a bystander?. Musculoskeletal care, 20(2), 416-428. https://doi.org/10.1002/msc.1636
MLA
Jain, Nibha, et al. "Cannabinoids in rheumatology: Friend, foe or a bystander?." Musculoskeletal care, 2022. https://doi.org/10.1002/msc.1636
RethinkTHC
RethinkTHC Research Database. "Cannabinoids in rheumatology: Friend, foe or a bystander?" RTHC-03928. Retrieved from https://rethinkthc.com/research/jain-2022-cannabinoids-in-rheumatology-friend
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.